Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,432,059 papers from all fields of science
Search
Sign In
Create Free Account
ganitumab
A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (1)
AMG 479
NCIt Antineoplastic Agent Terminology
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic…
C. Eng
,
E. Cutsem
,
+10 authors
J. Tabernero
2015
Corpus ID: 79402669
694 Background: Pmab, R, and G are fully human monoclonal antibodies that target EGFR, HGF, and IGF-1R, respectively. In part 2…
Expand
2014
2014
Cancer Therapy : Preclinical Ganitumab ( AMG 479 ) Inhibits IGF-II – Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
P. Beltran
,
F. Calzone
,
+11 authors
G. Konecny
2014
Corpus ID: 73639988
Purpose: Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the pathogenesis of ovarian cancer. Ganitumab is…
Expand
2013
2013
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG…
B. Glisson
,
A. Każarnowicz
,
+12 authors
S. Dubey
2013
Corpus ID: 79383575
2012
2012
Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers
Malorye Allison
Nature Biotechnology
2012
Corpus ID: 1737188
2012
2012
FDA prevails in stem cell trial
L. Defrancesco
Nature Biotechnology
2012
Corpus ID: 36074548
2012
2012
Drug companies look to biomarkers to salvage cancer target
E. Dolgin
Nature Network Boston
2012
Corpus ID: 205382344
The announcement last month that the biotech powerhouse Amgen was terminating a late-stage pancreatic cancer trial added another…
Expand
2012
2012
GM beets approved—finally
E. Waltz
Nature Biotechnology
2012
Corpus ID: 37384476
volume 30 number 10 oCTober 2012 nature biotechnology The news that Thousand Oaks, California– based Amgen halted the phase 3…
Expand
2012
2012
Abstract LB-257: Ganitumab (AMG 479), an anti IGF-1R antibody, inhibits the proliferation of melanoma cells
E. Euw
,
Veerauo Konkankit
,
+4 authors
D. Slamon
2012
Corpus ID: 72742792
2012
2012
Biologics clinical trials, research, and FDA actions.
M. Dalzell
Biotechnology healthcare
2012
Corpus ID: 36866590
Hopes raised, hopes dashed — the last half of 2012 has seen plenty of both. Enthusiasm over a bumper crop of U.S. Food and Drug…
Expand
2011
2011
PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC…
C. Eng
,
E. Nowara
,
+11 authors
E. Cutsem
2011
Corpus ID: 79056340